Drugs / JS109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05824455 | Mar → Sep 2023 | cancer | Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-11 | Shanghai Junshi Bioscience Co., Ltd. | Results 君实生物PARP抑制剂senaparib用于晚期卵巢癌全人群一线维持治疗的III期临床研究达到主要研究终点 junshipharma.com ↗
独立数据监查委员会（IDMC）判定研究的主要终点达到方案预设的优效界值。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-11 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物PARP抑制剂senaparib用于晚期卵巢癌全人群一线维持治疗的III期临床研究达到主要研究终点 junshipharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05824455 ↗ |
| Known as | IMP4297 | “A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors” NCT05824455 ↗ |
| Route | Oral | “JS109 PO,QD, q3w” NCT05824455 ↗ |